


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Davis Memorial Hospital dba Davis Medical Center</p> <p>2. P.O. Box 1484 Elkins, WV 26241-1484</p>		<p>In accordance with letter dated May 31, 2024,</p>	<p>4. Expiration Date: August 31, 2037</p>
		<p>3. License No.: 47-24864-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-29484 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Lutetium-177 permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1.5 curies total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For parenteral administration of Lu-177 permitted by 10 CFR 35.300 for which the patient can be released under the provision of 10 CFR 35.75.</p>



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 47-24864-01

Docket or Reference No.:  
030-29484

Amendment No. 32

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at: 812 Gorman Avenue, Elkins, West Virginia, 26241

11. The Radiation Safety Officer (RSO) for this license is Patrick Alex Brown, MD.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Material and Use

Patrick Alexander Brown, M.D.

10 CFR 35.100, 10 CFR 35.200

Charles D. Burtner, M.D.

10 CFR 35.100, 10 CFR 35.200;

Frederick J. Gabriel, M.D.

10 CFR 35.100, 10 CFR 35.200

Michael E. Galloway, M.D.

10 CFR 35.300 (limited to parenteral administration of Lu-177)

Evan G. Kupec, M. D.

10 CFR 35.100, 10 CFR 35.200

Jon LaPlante, M.D.

10 CFR 35.100, 10 CFR 35.200

John Leon, M.D.

10 CFR 35.100, 10 CFR 35.200;

Garret W. Stover, M. D.

10 CFR 35.100, 10 CFR 35.200

Walter Parke Thrush, M.D.

10 CFR 35.100, 10 CFR 35.200;

Wesley David Tuel, M. D.

10 CFR 35.100, 10 CFR 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 47-24864-01

Docket or Reference No.:  
030-29484

Amendment No. 32

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Application dated March 18, 2022 [ML22096A302]
  - B. Letter dated May 13, 2022 [ML22153A168]
  - C. Letters dated March 8, 2024 [ML24073A027], and May 9, 2024 [ML24135A258]
  - D. Letter dated July 29, 2024 [ML24212A081]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 27, 2024

By: \_\_\_\_\_

Jason vonEhr  
Region 1